Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Pseudomonas aeruginosa Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia
Abstract
:1. Introduction
2. Case Presentation
3. Discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Reynolds, D.; Kollef, M. The epidemiology and pathogenesis and treatment of pseudomonas aeruginosa infections: An update. Drugs 2021, 81, 2117–2131. [Google Scholar] [CrossRef] [PubMed]
- Center for Disease Control and Prevention. Pseudomonas Aeruginosa in Healthcare Settings. Available online: https://www.cdc.gov/hai/organisms/pseudomonas.html (accessed on 1 July 2023).
- Kollef, M.H.; Chastre, J.; Fagon, J.Y.; François, B.; Niederman, M.S.; Rello, J.; Torres, A.; Vincent, J.L.; Wunderink, R.G.; Go, K.W.; et al. Global prospective epidemiologic and surveillance study of ventilator-associated pneumonia due to Pseudomonas aeruginosa. Crit. Care Med. 2014, 42, 2178–2187. [Google Scholar] [CrossRef] [PubMed]
- Le Floch, R.; Naux, E.; Arnould, J.F. L’infection bactérienne chez le patient brûlé. Ann. Burns Fire Disasters 2015, 28, 94–104. [Google Scholar] [PubMed]
- American Burn Association. National Burn Repository Report of Data from 2006–2015. Available online: https://ameriburn.org/wp-content/uploads/2017/05/2016abanbr_final_42816.pdf (accessed on 5 June 2023).
- Vinsonneau, C.; Oueslati, H.; Benytamina, M. Immunologie et infection. In Les Brûlures; Echinard, C., Latarjet, J.P., Eds.; Elsevier Masson: Paris, France, 2010; pp. 67–76. [Google Scholar]
- Strassle, P.D.; Williams, F.N.; Weber, D.J.; Sickbert-Bennett, E.E.; Lachiewicz, A.M.; Napravnik, S.; Jones, S.W.; Cairns, B.A.; van Duin, D. Risk factors for healthcare-associated infections in adult burn patients. Infect. Control Hosp. Epidemiol. 2017, 38, 1441–1448. [Google Scholar] [CrossRef] [PubMed]
- Norbury, W.; Herndon, D.N.; Tanksley, J.; Jeschke, M.G.; Finnerty, C.C., on behalf of the Scientific Study Committee of the Surgical Infection Society. Infection in burns. Surg. Infect. 2016, 17, 250–255. [Google Scholar] [CrossRef] [PubMed]
- Ravat, F.; Fontaine, M.; Latarjet, J.; Voulliaume, D. Brûlures: Épidémiologie, évaluation, offre de soins [Burn: Epidemiology, evaluation, organisation of care]. Rev. Prat. 2018, 68, 1078–1082. (In French) [Google Scholar] [PubMed]
- Vincent, J.L.; Sakr, Y.; Singer, M.; Martin-Loeches, I.; Machado, F.R.; Marshall, J.C.; Finfer, S.; Pelosi, P.; Brazzi, L.; Aditianingsih, D.; et al. Prevalence and outcomes of infection among patients in intensive care units in 2017. JAMA 2020, 323, 1478–1487. [Google Scholar] [CrossRef]
- Papazian, L.; Klompas, M.; Luyt, C.E. Ventilator-associated pneumonia in adults: A narrative review. Intensive Care Med. 2020, 46, 888–906. [Google Scholar] [CrossRef]
- Gupta, R.; Malik, A.; Rizvi, M.; Ahmed, M.; Singh, A. Epidemiology of multidrug-resistant Gram-negative pathogens isolated from ventilator-associated pneumonia in ICU patients. J. Glob. Antimicrob. Resist. 2017, 9, 47–50. [Google Scholar] [CrossRef]
- Kula, B.E.; Hudson, D.; Sligl, W.I. Pseudomonas aeruginosa infection in intensive care: Epidemiology, outcomes, and antimicrobial susceptibilities. J. Assoc. Med. Microbiol. Infect. Dis. Can. 2020, 5, 130–138. [Google Scholar] [CrossRef] [PubMed]
- Fujitani, S.; Hsin-Yun, S.; Yu, V.L.; Weingarten, J.A. Pneumonia due to Pseudomonas aeruginosa: Part I: Epidemiology, clinical diagnosis, and source. Chest 2011, 139, 909–919. [Google Scholar] [CrossRef] [PubMed]
- Micek, S.T.; Kollef, M.H.; Torres, A.; Chen, C.; Rello, J.; Chastre, J.; Antonelli, M.; Welte, T.; Clair, B.; Ostermann, H.; et al. Pseudomonas aeruginosa nosocomial pneumonia: Impact of pneumonia classification. Infect. Control Hosp. Epidemiol. 2015, 36, 1190–1197. [Google Scholar] [CrossRef] [PubMed]
- Jarrell, A.S.; Kruer, R.M.; Berescu, L.D.; Pronovost, P.J.; Trivedi, J.B. Factors associated with in-hospital mortality among critically ill surgical patients with multidrug-resistant Gram-negative infections. J. Crit. Care 2018, 43, 321–326. [Google Scholar] [CrossRef] [PubMed]
- Azzopardi, E.A.; Azzopardi, E.; Camilleri, L.; Villapalos, J.; Boyce, D.E.; Dziewulski, P.; Dickson, W.A.; Whitaker, I.S. Gram negative wound infection in hospitalised adult burn patients–systematic review and metanalysis. PLoS ONE 2014, 9, e95042. [Google Scholar] [CrossRef] [PubMed]
- De Oliveira, D.M.P.; Forde, B.M.; Kidd, T.J.; Harris, P.N.A.; Schembri, M.A.; Beatson, S.A.; Paterson, D.L.; Walker, M.J. Antimicrobial Resistance in ESKAPE Pathogens. Clin. Microbiol. Rev. 2020, 33, e00181-19. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention. Multidrug-Resistant Pseudomonas aeruginosa. Available online: https://arpsp.cdc.gov/profile/antibiotic-resistance/mdr-empseudomonas-aeruginosaem (accessed on 23 September 2023).
- Center for Disease Control and Prevention. HAI Pathogens and Antimicrobial Resistance Report, 2018–2021. Available online: https://www.cdc.gov/nhsn/hai-report/data-tables-adult/index.html (accessed on 17 April 2024).
- World Health Organization. WHO Publishes List of Bacteria for Which New Antibiotics Are Urgently Needed. Available online: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed on 15 October 2023).
- Reyes, J.; Komarow, L.; Chen, L.; Ge, L.; Hanson, B.M.; Cober, E.; Herc, E.; Alenazi, T.; Kaye, K.S.; Garcia-Diaz, J.; et al. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): A prospective cohort study. Lancet Microbe 2023, 4, e159–e170. [Google Scholar] [CrossRef] [PubMed]
- Domingo-Calap, P.; Delgado-Martínez, J. Bacteriophages: Protagonists of a Post-Antibiotic Era. Antibiotics 2018, 7, 66. [Google Scholar] [CrossRef]
- Tortuel, D.; Tahrioui, A.; David, A.; Cambronel, M.; Nilly, F.; Clamens, T.; Maillot, O.; Barreau, M.; Feuilloley, M.G.J.; Lesouhaitier, O.; et al. Pf4 phage variant infection reduces virulence-associated traits in Pseudomonas aeruginosa. Microbiol. Spectr. 2022, 10, e0154822. [Google Scholar] [CrossRef]
- Curran, C.S.; Bolig, T.; Torabi-Parizi, P. Mechanisms and targeted therapies for Pseudomonas aeruginosa lung infection. Am. J. Respir. Crit. Care Med. 2018, 197, 708–727. [Google Scholar] [CrossRef]
- Yang, Z.; Shi, Y.; Zhang, C.; Luo, X.; Chen, Y.; Peng, Y.; Gong, Y. Lytic bacteriophage screening strategies for multidrug-resistant bloodstream infections in a burn intensive care unit. Med. Sci. Monit. 2019, 25, 8352–8362. [Google Scholar] [CrossRef]
- Chegini, Z.; Khoshbayan, A.; Taati Moghadam, M.; Farahani, I.; Jazireian, P.; Shariati, A. Bacteriophage therapy against Pseudomonas aeruginosa biofilms: A review. Ann. Clin. Microbiol. Antimicrob. 2020, 19, 45. [Google Scholar] [CrossRef] [PubMed]
- Eiselt, V.A.; Bereswill, S.; Heimesaat, M.M. Phage therapy in lung infections caused by multidrug-resistant Pseudomonas aeruginosa—A literature review. Eur. J. Microbiol. Immunol. 2024, 14, 1–12. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- ARDS Definition Task Force; Ranieri, V.M.; Rubenfeld, G.D.; Thompson, B.T.; Ferguson, N.D.; Caldwell, E.; Fan, E.; Camporota, L.; Slutsky, A.S. Acute respiratory distress syndrome: The Berlin Definition. JAMA 2012, 307, 2526–2533. [Google Scholar] [CrossRef] [PubMed]
- Zilberberg, M.D.; Shorr, A.F. Ventilator-associated pneumonia: The clinical pulmonary infection score as a surrogate for diagnostics and outcome. Clin. Infect. Dis. 2010, 1 (Suppl. S1), S131–S135. [Google Scholar] [CrossRef]
- Oechslin, F.; Piccardi, P.; Mancini, S.; Gabard, J.; Moreillon, P.; Entenza, J.M.; Resch, G.; Que, Y.A. Synergistic Interaction between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence. J. Infect. Dis. 2017, 215, 703–712. [Google Scholar] [CrossRef]
- Guillon, A.; Pardessus, J.; L’Hostis, G.; Fevre, C.; Barc, C.; Dalloneau, E.; Jouan, Y.; Bodier-Montagutelli, E.; Perez, Y.; Thorey, C.; et al. Inhaled bacteriophage therapy in a porcine model of pneumonia caused by Pseudomonas aeruginosa during mechanical ventilation. Br. J. Pharmacol. 2021, 178, 3829–3842. [Google Scholar] [CrossRef]
- Le Guellec, S.; Pardessus, J.; Bodier-Montagutelli, E.; L’hostis, G.; Dalloneau, E.; Piel, D.; Samaï, H.C.; Guillon, A.; Mujic, E.; Guillot-Combe, E.; et al. Administration of Bacteriophages via Nebulization during Mechanical Ventilation: In Vitro Study and Lung Deposition in Macaques. Viruses 2023, 15, 602. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Ferry, T.; Boucher, F.; Fevre, C.; Perpoint, T.; Chateau, J.; Petitjean, C.; Josse, J.; Chidiac, C.; L’hostis, G.; Leboucher, G.; et al. Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected cocktail of bacteriophages. J. Antimicrob. Chemother. 2018, 73, 2901–2903. [Google Scholar] [CrossRef] [PubMed]
- Ferry, T.; Kolenda, C.; Batailler, C.; Gaillard, R.; Gustave, C.-A.; Lustig, S.; Fevre, C.; Petitjean, C.; Leboucher, G.; Laurent, F.; et al. Case Report: Arthroscopic “Debridement Antibiotics and Implant Retention” with Local Injection of Personalized Phage Therapy to Salvage a Relapsing Pseudomonas aeruginosa Prosthetic Knee Infection. Front. Med. 2021, 8, 569159. [Google Scholar] [CrossRef]
- Gill, J.S.; Arora, S.; Khanna, S.P.; Kumar, K.H. Prevalence of multidrug-resistant, extensively drug-resistant, and pandrug-resistant Pseudomonas aeruginosa from a tertiary level intensive care unit. J. Glob. Infect. Dis. 2016, 8, 155–159. [Google Scholar] [CrossRef]
- Green, S.; Kaelber, J.; Ma, L.; Trautner, B.W.; Ramig, R.F.; Maresso, A.W. Bacteriophages from ExPEC reservoirs kill pandemic multidrug-resistant strains of clonal group ST131 in animal models of bacteremia. Sci. Rep. 2017, 7, 46151. [Google Scholar] [CrossRef]
- Greenhalgh, D.G.; Saffle, J.R.; Holmes, J.H.T., 4th; Gamelli, R.L.; Palmieri, T.L.; Horton, J.W.; Tompkins, R.G.; Traber, D.L.; Mozingo, D.W.; Deitch, E.A.; et al. American Burn Association consensus conference to define sepsis and infection in burns. J. Burn. Care Res. 2007, 28, 776–790. [Google Scholar] [CrossRef] [PubMed]
- Shankar-Hari, M.; Phillips, G.S.; Levy, M.L.; Seymour, C.W.; Liu, V.X.; Deutschman, C.S.; Angus, D.C.; Rubenfeld, G.D.; Singer, M.; Sepsis Definitions Task Force. Developing a new definition and assessing new clinical criteria for septic shock: For the third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016, 315, 775–787. [Google Scholar] [CrossRef] [PubMed]
- Gallaghe, J.J.; Williams-Bouyer, N.; Villarreal, C.; Heggers, J.P.; Herndon, D. Treatment of infection in burns. In Total Burn Care, 3rd ed.; Herndon, D.H., Ed.; Saunders-Elseviers: Philadelphia, PA, USA, 2007; pp. 136–176. [Google Scholar]
- Lord, J.M.; Midwinter, M.J.; Chen, Y.F.; Belli, A.; Brohi, K.; Kovacs, E.J.; Koenderman, L.; Kubes, P.; Lilford, R.J. The systemic immune response to trauma: An overview of pathophysiology and treatment. Lancet 2014, 384, 1455–1465. [Google Scholar] [CrossRef] [PubMed]
- Moins-Teisserenc, H.; Cordeiro, D.J.; Audigier, V.; Ressaire, Q.; Benyamina, M.; Lambert, J.; Maki, G.; Homyrda, L.; Toubert, A.; Legrand, M. Severe altered immune status after burn injury is associated with bacterial infection and septic shock. Front. Immunol. 2021, 12, 586195. [Google Scholar] [CrossRef] [PubMed]
- Sierawska, O.; Małkowska, P.; Taskin, C.; Hrynkiewicz, R.; Mertowska, P.; Grywalska, E.; Korzeniowski, T.; Torres, K.; Surowiecka, A.; Niedźwiedzka-Rystwej, P.; et al. Innate immune system response to burn damage-focus on cytokine alteration. Int. J. Mol. Sci. 2022, 23, 716. [Google Scholar] [CrossRef] [PubMed]
- Robins, E.V. Immunosuppression of the burned patient. Crit. Care Nurs. Clin. N. Am. 1890, 1, 767–774, Erratum in Crit. Care Nurs. Clin. N. Am. 1990, 2, preceding xiii. [Google Scholar] [CrossRef]
- Kuznetsova, T.A.; Andryukov, B.G.; Besednova, N.N. Modern aspects of burn injury immunopathogenesis and prognostic immunobiochemical markers (mini-review). BioTech 2022, 11, 18. [Google Scholar] [CrossRef]
- Venet, F.; Lukaszewicz, A.C.; Payen, D.; Hotchkiss, R.; Monneret, G. Monitoring the immune response in sepsis: A rational approach to administration of immunoadjuvant therapies. Curr. Opin. Immunol. 2013, 25, 477–483. [Google Scholar] [CrossRef]
- Forel, J.M.; Chiche, L.; Thomas, G.; Mancini, J.; Farnarier, C.; Cognet, C.; Guervilly, C.; Daumas, A.; Vely, F.; Xéridat, F.; et al. Phenotype and functions of natural killer cells in critically-ill septic patients. PLoS ONE 2012, 7, e50446. [Google Scholar] [CrossRef]
- Bidar, F.; Bodinier, M.; Venet, F.; Lukaszewicz, A.C.; Brengel-Pesce, K.; Conti, F.; Quemeneur, L.; Leissner, P.; Tan, L.K.; Textoris, J.; et al. Concomitant assessment of monocyte hla-dr expression and ex vivo tnf-α release as markers of adverse outcome after various injuries-insights from the REALISM study. J. Clin. Med. 2021, 11, 96. [Google Scholar] [CrossRef] [PubMed]
- Perry, S.E.; Mostafa, S.M.; Wenstone, R.; Shenkin, A.; McLaughlin, P.J. Is low monocyte HLA-DR expression helpful to predict outcome in severe sepsis? Intensiv. Care Med. 2003, 29, 1245–1252. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.Y.; Wu, P.F.; Chen, C.S.; Chen, I.H.; Huang, W.T.; Wang, F.D. Trends in microbial profile of burn patients following an event of dust explosion at a tertiary medical center. BMC Infect. Dis. 2020, 20, 193. [Google Scholar] [CrossRef] [PubMed]
- Sagripanti, J.L.; Bonifacino, A. Resistance of Pseudomonas aeruginosa to liquid disinfectants on contaminated surfaces before formation of biofilms. J. AOAC Int. 2000, 83, 1415–1422. [Google Scholar] [CrossRef] [PubMed]
- Qin, S.; Xiao, W.; Zhou, C.; Pu, Q.; Deng, X.; Lan, L.; Liang, H.; Song, X.; Wu, M. Pseudomonas aeruginosa: Pathogenesis, virulence factors, antibiotic resistance, interaction with host, technology advances and emerging therapeutics. Signal Transduct. Target. Ther. 2022, 7, 199. [Google Scholar] [CrossRef] [PubMed]
- Muller, M.; Li, Z.; Maitz, P.K.M. Pseudomonas pyocyanin inhibits wound repair by inducing premature cellular senescence: Role for p38 mitogen-activated protein kinase. Burns 2009, 35, 500–508. [Google Scholar] [CrossRef]
- Turner, K.H.; Everett, J.; Trivedi, U.; Rumbaugh, K.P.; Whiteley, M. Requirements for Pseudomonas aeruginosa acute burn and chronic surgical wound infection. PLoS Genet. 2014, 10, e1004743. [Google Scholar] [CrossRef]
- O’Donnell, J.N.; Bidell, M.R.; Lodise, T.P. Approach to the treatment of patients with serious multidrug-resistant pseudomonas aeruginosa infections. Pharmacotherapy 2020, 40, 952–969. [Google Scholar] [CrossRef] [PubMed]
- Horcajada, J.P.; Montero, M.; Oliver, A.; Sorlí, L.; Luque, S.; Gómez-Zorrilla, S.; Benito, N.; Grau, S. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa infections. Clin. Microbiol. Rev. 2019, 32, e00031-19. [Google Scholar] [CrossRef]
- Fernandez, L.; Hancock, R.E. Adaptive and mutational resistance: Role of porins and efflux pumps in drug resistance. Clin. Microbiol. Rev. 2013, 26, 163. [Google Scholar] [CrossRef]
- Kalil, A.C.; Metersky, M.L.; Klompas, M.; Muscedere, J.; Sweeney, D.A.; Palmer, L.B.; Napolitano, L.M.; O’Grady, N.P.; Bartlett, J.G.; Carratalà, J.; et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin. Infect. Dis. 2016, 5, e61–e111. [Google Scholar] [CrossRef] [PubMed]
- Tamma, P.D.; Cosgrove, S.E.; Maragakis, L.L. Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev. 2012, 3, 450–470. [Google Scholar] [CrossRef] [PubMed]
- Kallel, H.; Bahloul, M.; Hergafi, L.; Akrout, M.; Ketata, W.; Chelly, H.; Hamida, C.B.; Rekik, N.; Hammami, A.; Bouaziz, M. Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU. Int. J. Antimicrob. Agents 2006, 28, 366–369. [Google Scholar] [CrossRef] [PubMed]
- Kwa, A.L.; Loh, C.; Low, J.G.; Kurup, A.; Tam, V.H. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis. 2005, 41, 754–757. [Google Scholar] [CrossRef] [PubMed]
- Lu, Q.; Girardi, C.; Zhang, M.; Bouhemad, B.; Louchahi, K.; Petitjean, O.; Wallet, F.; Becquemin, M.H.; Le Naour, G.; Marquette, C.H.; et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensiv. Care Med. 2010, 36, 1147–1155. [Google Scholar] [CrossRef] [PubMed]
- Ratjen, F.; Rietschel, E.; Kasel, D.; Schwiertz, R.; Starke, K.; Beier, H.; van Koningsbruggen, S.; Grasemann, H. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 2006, 57, 306–311. [Google Scholar] [CrossRef] [PubMed]
- Tsuji, B.T.; Pogue, J.M.; Zavascki, A.P.; Paul, M.; Daikos, G.L.; Forrest, A.; Giacobbe, D.R.; Viscoli, C.; Giamarellou, H.; Karaiskos, I.; et al. International consensus guidelines for the optimal use of the polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019, 39, 10–39. [Google Scholar] [CrossRef]
- Lu, Q.; Luo, R.; Bodin, L.; Yang, J.; Zahr, N.; Aubry, A.; Golmard, J.L.; Rouby, J.J.; Nebulized antibiotics study group. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology 2012, 117, 1335–1347. [Google Scholar] [CrossRef] [PubMed]
- Athanassa, Z.E.; Markantonis, S.L.; Fousteri, M.Z.; Myrianthefs, P.M.; Boutzouka, E.G.; Tsakris, A.; Baltopoulos, G.J. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensiv. Care Med. 2012, 38, 1779–1786. [Google Scholar] [CrossRef]
- Ari, A.; Atalay, O.T.; Harwood, R.; Sheard, M.M.; Aljamhan, E.A.; Fink, J.B. Influence of nebulizer type, position and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respir Care 2010, 55, 845–851. [Google Scholar]
- Abdellatif, S.; Trifi, A.; Daly, F.; Mahjoub, K.; Nasri, R.; Ben Lakhal, S. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: A prospective, randomised trial. Ann. Intensiv. Care 2016, 6, 26. [Google Scholar] [CrossRef]
- Maciejewska, B.; Olszak, T.; Drulis-Kawa, Z. Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: An ambitious and also a realistic application? Appl. Microbiol. Biotechnol. 2018, 102, 2563–2581. [Google Scholar] [CrossRef] [PubMed]
- Jault, P.; Leclerc, T.; Jennes, S.; Pirnay, J.P.; Que, Y.A.; Resch, G.; Rousseau, A.F.; Ravat, F.; Carsin, H.; Le Floch, R.; et al. Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): A randomised, controlled, double-blind phase 1/2 trial. Lancet Infect. Dis. 2019, 19, 35–45. [Google Scholar] [CrossRef] [PubMed]
- Roach, D.R.; Leung, C.Y.; Henry, M.; Morello, E.; Singh, D.; Di Santo, J.P.; Weitz, J.S.; Debarbieux, L. Synergy between the host immune system and bacteriophage is essential for successful phage therapy against an acute respiratory pathogen. Cell Host Microbe 2017, 22, 38–47.e4. [Google Scholar] [CrossRef] [PubMed]
First VAP + Bactermia + Graft lysis | Second VAP +Bactermia + Graft lysis | Third VAP + Bacteremia | Mild Pneumonia + Bacteremia+ Graflt lysis | |
---|---|---|---|---|
Ticarcilline | R | R | R | R |
Ticarcilline + Clavulanate | R | R | R | R |
Piperacilline | R | R | R | R |
Piperacilline + Tazobactam | R MIC > 32 | R MIC >32 | R MIC >32 | R MIC >32 |
Ceftazidime | R | R | R | R |
Aztreonam | R MIC > 32 | R MIC > 32 | R MIC > 32 | R |
Imipenem | R MIC > 8 | R MIC > 8 | R MIC > 8 | R MIC >8 |
Meropenem | R MIC: 16 | R MIC: 16 | R | R |
Tobramycine | R | R | R | R |
Ciprofloxacine | R | R | R | R |
Levofloxacine | R | R | R | R |
Cotrimoxazole | R | R | R | R |
Colistine | S MIC: 2 | S MIC: 1 | S MIC: 2 | S MIC: 2 |
Ceftazidim + Avibactam | S MIC: 4 | R MIC: 16 | R MIC: 16 | R MIC: 16 |
Ceftolozane + Tazobactam | R MIC: 4 | R MIC: 4 | S MIC: 4 | S MIC: 4 |
Cefepim | R MIC > 16 | R MIC > 16 | R MIC > 16 | R MIC: 16 |
Cefiderocol | S MIC: 0.500 | S MIC: 0.500 | S MIC: 0.500 | S MIC: 0.500 |
Imipenem + Relebactam | S MIC: 2 | S MIC: 4 | S MIC: 2 | R MIC > 8 |
Meropenem + Vaborbactam | R MIC: 16 | R CMI: 16 | R CMI: 16 | R CMI: 16 |
Tobramycine | R MIC >4 | R MIC >4 | R MIC >4 | R MIC > 4 |
Amikacine | R MIC > 32 | R MIC > 32 | R MIC > 32 | R MIC > 32 |
Tigecycline | R MIC > 1 | R MIC > 1 | R MIC > 1 | R MIC > 1 |
Eravacycline | R MIC > 0.500 | R | R MIC > 0.500 | R MIC > 0.500 |
Fosfomycine | S MIC: 64 | R |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Teney, C.; Poupelin, J.-C.; Briot, T.; Le Bouar, M.; Fevre, C.; Brosset, S.; Martin, O.; Valour, F.; Roussel-Gaillard, T.; Leboucher, G.; et al. Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Pseudomonas aeruginosa Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia. Viruses 2024, 16, 1080. https://doi.org/10.3390/v16071080
Teney C, Poupelin J-C, Briot T, Le Bouar M, Fevre C, Brosset S, Martin O, Valour F, Roussel-Gaillard T, Leboucher G, et al. Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Pseudomonas aeruginosa Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia. Viruses. 2024; 16(7):1080. https://doi.org/10.3390/v16071080
Chicago/Turabian StyleTeney, Cécile, Jean-Charles Poupelin, Thomas Briot, Myrtille Le Bouar, Cindy Fevre, Sophie Brosset, Olivier Martin, Florent Valour, Tiphaine Roussel-Gaillard, Gilles Leboucher, and et al. 2024. "Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Pseudomonas aeruginosa Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia" Viruses 16, no. 7: 1080. https://doi.org/10.3390/v16071080
APA StyleTeney, C., Poupelin, J. -C., Briot, T., Le Bouar, M., Fevre, C., Brosset, S., Martin, O., Valour, F., Roussel-Gaillard, T., Leboucher, G., Ader, F., Lukaszewicz, A. -C., & Ferry, T., on behalf of the PHAGEinLYON Clinic Study Group. (2024). Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant Pseudomonas aeruginosa Responsible for Relapsing Ventilator-Associated Pneumonia and Bacteriemia. Viruses, 16(7), 1080. https://doi.org/10.3390/v16071080